XML 25 R12.htm IDEA: XBRL DOCUMENT
v3.20.2

Balance Sheet Disclosures | 9 Months Ended
--- | ---
Sep. 30, 2020
Balance Sheet Related Disclosures [Abstract] |
Balance Sheet Disclosures | Note 4 - Balance Sheet Disclosures Property and equipment consist of the following (in thousands):
|  | September 30, 2020 |  |  | December 31, 2019 |
Lab equipment |  | $ | 5,741 |  |  | $ | 4,221 |
Leasehold improvements |  |  | 1,778 |  |  |  | 1,894 |
Computer equipment |  |  | 871 |  |  |  | 869 |
Furniture and fixtures |  |  | 424 |  |  |  | 427 |
Software |  |  | 633 |  |  |  | 503 |
Construction in process |  |  | 40 |  |  |  | 592 |
|  |  | 9,487 |  |  |  | 8,506 |
Less accumulated depreciation |  |  | (6,482 | ) |  |  | (6,386 | )
Total property and equipment |  | $ | 3,005 |  |  | $ | 2,120 |
Depreciation expense for each of the three and nine months ended September 30, 2020 and 2019 was $$0.2 million and 0.6 million, respectively. Intangible assets consist of the following (in thousands):
|  | September 30, 2020 |  |  | December 31, 2019 |
Patents |  | $ | 1,393 |  |  | $ | 1,245 |
Less accumulated amortization |  |  | (475 | ) |  |  | (411 | )
|  | $ | 918 |  |  | $ | 834 |
Purchased technology |  | $ | 16,900 |  |  | $ | 16,900 |
Less accumulated amortization |  |  | (4,225 | ) |  |  | (2,817 | )
|  | $ | 12,675 |  |  | $ | 14,083 |
Purchase option |  |  | — |  |  | $ | 121 |
Less accumulated amortization |  |  | — |  |  |  | (17 | )
|  | $ | — |  |  | $ | 104 |
Trademarks (indefinite life) |  | $ | 74 |  |  | $ | 71 |
Total intangible assets |  | $ | 13,667 |  |  | $ | 15,092 |
The Company recorded amortization expense of $0.5 million and $1.6 million for the three and nine months ended September 30, 2020, respectively, and $0.5 million and $1.5 million for the three and nine months ended September 30, 2019, respectively. Amortization related to the remaining net intangible assets is scheduled to amortize as follows (in thousands):
Year Ending December 31, |  |  |  |
Remainder of 2020 |  | $ | 489 |
2021 |  |  | 1,944 |
2022 |  |  | 1,938 |
2023 |  |  | 1,936 |
2024 |  |  | 1,927 |
Thereafter |  |  | 5,359 |
Total future amortization expense |  | $ | 13,593 |
Accrued liabilities consist of the following (in thousands):
|  | September 30, 2020 |  |  | December 31, 2019 |
Compensation related accruals |  | $ | 2,688 |  |  | $ | 1,165 |
Accrued clinical trial expense |  |  | 699 |  |  |  | 620 |
Other expenses |  |  | 3,566 |  |  |  | 2,352 |
Warrant liability, current |  |  | — |  |  |  | 43 |
Total accrued liabilities |  | $ | 6,953 |  |  | $ | 4,180 |

X
- References No definition available. + Details
Name: | us-gaap_BalanceSheetRelatedDisclosuresAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -URI http://asc.fasb.org/topic&trid=2122208 + Details
Name: | us-gaap_SupplementalBalanceSheetDisclosuresTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration